102 related articles for article (PubMed ID: 10344035)
1. Clinical profile of saruplase: angiographic findings.
Meyer J
Int J Clin Pract Suppl; 1998 Nov; 99():9-15. PubMed ID: 10344035
[TBL] [Abstract][Full Text] [Related]
2. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
[TBL] [Abstract][Full Text] [Related]
3. [Pro-urokinase for infarct therapy].
Spiecker M; Meyer J
Herz; 1994 Dec; 19(6):326-35. PubMed ID: 7843689
[TBL] [Abstract][Full Text] [Related]
4. Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction.
Bär FW; Meyer J; Vermeer F; Michels R; Charbonnier B; Haerten K; Spiecker M; Macaya C; Hanssen M; Heras M; Boland JP; Morice MC; Dunn FG; Uebis R; Hamm C; Ayzenberg O; Strupp G; Withagen AJ; Klein W; Windeler J; Hopkins G; Barth H; von Fisenne MJ
Am J Cardiol; 1997 Mar; 79(6):727-32. PubMed ID: 9070549
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators.
Tebbe U; Michels R; Adgey J; Boland J; Caspi A; Charbonnier B; Windeler J; Barth H; Groves R; Hopkins GR; Fennell W; Betriu A; Ruda M; Mlczoch J
J Am Coll Cardiol; 1998 Mar; 31(3):487-93. PubMed ID: 9502624
[TBL] [Abstract][Full Text] [Related]
6. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
[TBL] [Abstract][Full Text] [Related]
7. Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI trial.
Spiecker M; Windeler J; Vermeer F; Michels R; Seabra-Gomes R; vom Dahl J; Kerber S; Verheugt FW; Westerhof PW; Bär FW; Nixdorff U; Barth H; Hopkins GR; von Fisenne MJ; Meyer J
Am Heart J; 1999 Sep; 138(3 Pt 1):518-24. PubMed ID: 10467203
[TBL] [Abstract][Full Text] [Related]
8. Saruplase is a safe and effective thrombolytic agent; observations in 1,698 patients: results of the PASS study. Practical Applications of Saruplase Study.
Vermeer F; Bösl I; Meyer J; Bär F; Charbonnier B; Windeler J; Barth H
J Thromb Thrombolysis; 1999 Aug; 8(2):143-50. PubMed ID: 10436145
[TBL] [Abstract][Full Text] [Related]
9. Thrombolytic treatment in acute myocardial infarction.
Verstraete M
Circulation; 1990 Sep; 82(3 Suppl):II96-109. PubMed ID: 2118432
[TBL] [Abstract][Full Text] [Related]
10. Time course of left ventricular function and coronary patency after saruplase vs streptokinase in acute myocardial infarction. The PRIMI Trial Study Group.
Schofer J; Lins M; Mathey DG; Sheehan FH
Eur Heart J; 1993 Jul; 14(7):958-63. PubMed ID: 8375422
[TBL] [Abstract][Full Text] [Related]
11. Saruplase in Myocardial Infarction.
Bär FW; Vermeer F; Michels R; Boland J; Meyer J; Hopkins G; Barth H; Grünzler WA
J Thromb Thrombolysis; 1995; 2(3):195-204. PubMed ID: 10608024
[TBL] [Abstract][Full Text] [Related]
12. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group.
Lancet; 1989 Apr; 1(8643):863-8. PubMed ID: 2564949
[TBL] [Abstract][Full Text] [Related]
13. Saruplase versus other fibrinolytic agents.
Michels HR
Int J Clin Pract Suppl; 1998 Nov; 99():21-2. PubMed ID: 10344037
[No Abstract] [Full Text] [Related]
14. Pharmacology and clinical trial results of saruplase (scuPA) in acute myocardial infarction.
Moser M; Bode C
Expert Opin Investig Drugs; 1999 Mar; 8(3):329-35. PubMed ID: 15992082
[TBL] [Abstract][Full Text] [Related]
15. New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group.
Weaver WD; Hartmann JR; Anderson JL; Reddy PS; Sobolski JC; Sasahara AA
J Am Coll Cardiol; 1994 Nov; 24(5):1242-8. PubMed ID: 7930246
[TBL] [Abstract][Full Text] [Related]
16. Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis.
Schneider J
Thromb Res; 1991 Dec; 64(6):677-89. PubMed ID: 1798957
[TBL] [Abstract][Full Text] [Related]
17. Mode of action and pharmacology of saruplase.
Vermeer F
Int J Clin Pract Suppl; 1998 Nov; 99():6-8. PubMed ID: 10344034
[No Abstract] [Full Text] [Related]
18. Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction--results from the PRIMI trial.
Ostermann H; Schmitz-Huebner U; Windeler J; Bär F; Meyer J; van de Loo J
Eur Heart J; 1992 Sep; 13(9):1225-32. PubMed ID: 1396833
[TBL] [Abstract][Full Text] [Related]
19. [t-PA in thrombolytic therapy of acute myocardial infarct].
Rutsch W; Schmutzler H
Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
[TBL] [Abstract][Full Text] [Related]
20. [Thrombolytic therapy in acute myocardial infarct].
Verstraete M
Recenti Prog Med; 1990 Apr; 81(4):287-98. PubMed ID: 2198644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
